人肠抑素
人肠抑素 性质
| 密度 | 1.54±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | −20°C |
| 溶解度 | 在无菌水中的溶解度为 0.70 mg/ml |
| 酸度系数(pKa) | 3.60±0.21(Predicted) |
| 形态 | 冻干固体。 |
人肠抑素 用途与合成方法
|
Human Endogenous Metabolite
|
In the perfused ratpancreas, Enterostatin, at 100 mM, inhibits the insulin response to 9 mM glucose (by 70%), 0.1 mM tolbutamide (by 40%), and 5 mM arginine (by 70%).
Chronically, enterostatin reduces fat intake, bodyweight, and body fat. This response may involve multiple metabolic effects of enterostatin, which include a reduction of insulin secretion, an increase in sympathetic drive to brown adipose tissue, and the stimulation of adrenal corticosteroid secretion. Enterostatin enhances memory consolidation after central or oral administration at a dose of 10 nmol/mouse or 300 mg/kg, respectively, in a step-through type passive avoidance test in mice. A dose of 38 nmol of enterostatin gives a significant inhibition of high-fat food intake, while at a higher dose of 76 nmol the inhibiting effect is lost. During the first hour, after injection of enterostatin, there is even a slight increase in food intake.
